Plain answer: In the 68-week REDEFINE 9 trial, the estimated average weight loss with investigational CagriSema was 20.7% and 21.0% at the two studied dose levels under an analysis that estimates the effect if participants stayed on treatment. A second analysis, which includes treatment discontinuation and use of rescue intervention in the question it asks, estimated 19.4% and 18.6%. These are two analyses of the same trial, not four different studies. Neither set of numbers tells us that one CagriSema dose outperformed the other.
What did REDEFINE 9 test?
Researchers randomly assigned 309 adults with obesity, or with overweight and at least one related complication, to one of two CagriSema dose groups or matching placebo. Participants did not have diabetes. The study was blinded within each dose level, lasted 68 weeks for the main outcomes, and included nutrition and physical activity counseling. Each dose was evaluated against pooled placebo. The trial was funded by Novo Nordisk and published on November 14, 2026 in The Lancet Diabetes & Endocrinology. Its registry number is NCT06388187.
| Analysis question | CagriSema 1.7 mg / 1.7 mg | CagriSema 1.0 mg / 1.0 mg | Pooled placebo |
|---|---|---|---|
| If participants adhered to treatment (efficacy estimand) | 20.7% | 21.0% | 2.0% |
| Regardless of discontinuation or rescue intervention (treatment-regimen estimand) | 19.4% | 18.6% | 4.6% |
Source: REDEFINE 9 publication for trial design and primary reported results; Novo Nordisk’s November 14 results release for both estimand tables. The percentages are estimated group averages, not an individual’s expected result. The mg figures identify the trial groups; they are not a use or mixing instruction.
Why are there two answers?
A trial has to define what it wants its result to mean. The efficacy estimand estimates the treatment effect if participants adhered to the assigned treatment. The treatment-regimen estimand estimates the effect regardless of whether they discontinued treatment or used a weight-management rescue intervention. Different questions and statistical handling of incomplete outcomes can produce different estimates. Neither percentage should be presented without its analysis label.
The trial also reported that 291 of 309 randomized participants completed the study and 254 were on treatment at week 68. Those counts help explain why the handling of discontinuation matters; they do not let us calculate either estimand by simply averaging the people who remained on treatment.
Did the lower dose work better?
REDEFINE 9 cannot establish that. The 21.0% and 20.7% figures are close, but the study was not powered to detect differences between the two CagriSema doses. Its planned comparisons tested each dose against placebo. Reading the larger of two headline percentages as a dose-ranking result would answer a question this trial was not designed to settle.
What about side effects?
Adverse events were reported by 99% of participants receiving the 1.7 mg / 1.7 mg combination, 95% receiving the 1.0 mg / 1.0 mg combination, and 91% receiving placebo. The published abstract describes most events as mild or moderate and related to the digestive system. A group average for weight change does not resolve the benefit and risk for an individual.
What do these results not show?
REDEFINE 9 had no tirzepatide or semaglutide-only comparison group, so its percentages cannot establish that CagriSema is better or worse than either medicine. Results from another trial may involve a different population, dose, duration, comparator, or analysis. This study also tested a controlled clinical trial product; it does not verify the identity, sterility, or suitability for human use of an online research blend.
As of the November 16, 2026 source check, Novo Nordisk described CagriSema as investigational and not approved in the United States. The study adds evidence for the two tested levels versus placebo. It does not establish a personal treatment plan or a protocol for a separately sold vial.
Keep exploring
For the ingredients and what each contributes, read our CagriSema components guide. For a different molecule with related pathways, see zenagamtide versus CagriSema. Read how PeptideWHY handles sources and corrections.
Source check: November 16, 2026.